Missense mutations influence protein abundance in prostate cancer. Using a SILAC-based quantitative proteomics approach, we identified significant proteomic differences between healthy and tumor ...
Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer. Association of ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601 Sequencing data from 56,965 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results